Acquisitions23 Sept 2026, 06:10 pm
Jagsonpal Pharma Acquires Group Pharma Wellness Portfolio for ₹46.7 Cr
AI Summary
Jagsonpal Pharmaceuticals Limited has entered into a Business Transfer Agreement with Group Pharmaceuticals Limited to acquire its Wellness Portfolio for an initial consideration of ₹23.7 crores, with an additional consideration of up to ₹23.0 crores linked to FY 2027-28 sales, capped at a total of ₹46.7 crores. The acquisition, structured as a slump sale, is expected to be completed by November 1, 2026. This strategic move aims to strengthen Jagsonpal's pharmaceutical portfolio, expand its presence in relevant therapeutic segments, and enhance market reach. The acquired portfolio had a turnover of ₹24.6 Crores in FY 2025-26 and operates in the pharmaceutical industry.
Key Highlights
- Jagsonpal Pharma acquires Group Pharma's Wellness Portfolio via slump sale.
- Total consideration capped at ₹46.7 Cr, including ₹23.7 Cr initial payment.
- Acquisition aims to strengthen product portfolio and market presence.
- Expected completion by November 1, 2026.
- Portfolio generated ₹24.6 Cr turnover in FY 2025-26.
Price Impact
More from JAGSNPHARM